Lymphatic Osteopathic Manipulative Medicine to Enhance Coronavirus (COVID-19) Vaccination Efficacy

Rowan University

Overview

The purpose of this project is to study the impact of Osteopathic Manipulative Medicine (OMM) treatments, such as lymphatic myofascial release and thoracic pump techniques severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels in patients who receive the mRNA-1273 (Moderna) COVID-19 vaccine and to consider if these OMM strategies allow a stronger more robust immune response.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Conditions

COVID-19

Interventions

Lymphatic OMMOTHER

Patients receive lymphatic myofascial release and thoracic pump techniques.

Light TouchOTHER

Patients receive a series of light touch techniques.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Inclusion criteria will include age greater than 18 years old and having safely received the COVID-19 vaccine. Exclusion Criteria: * Exclusion criteria will include age under 18 years old, malignancy/cancer, ongoing infection, coagulopathy history, use of anticoagulant medications, and fracture or acute injury of the torso neck or upper extremities. Lymphatic OMM is safe during pregnancy and this does not need to be an exclusion criteria.

Locations (1)

Rowan University School of Osteopathic Medicine

Stratford, New Jersey, United States

Outcomes

Primary Outcomes

severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels

Antibody levels collected via blood draw

Time frame: The day of first vaccine dose (baseline), the day of second vaccine dose (at about 4-weeks post first vaccine dose), and 2-weeks post second vaccine dose (at about 6-weeks post first vaccine dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.